Co-evolution of immunity and seasonal influenza viruses

1. Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285–1300 (2018).

   Article 
   PubMed 

   Google Scholar 

2. Chambers, B. S., Parkhouse, K., Ross, T. M., Alby, K. & Hensley, S. E. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep. 12, 1–6 (2015).

   Article 
   CAS 
   PubMed 
   PubMed Central 

   Google Scholar 

3. Tenforde, M. W. et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States—2019–2020. Clin. Infect. Dis. 73, e4244–e4250 (2021).

   Article 
   CAS 
   PubMed 

   Google Scholar 

4. Petrova, V. N. & Russell, C. A. The evolution of seasonal influenza viruses. Nat. Rev. Microbiol. 16, 47–60 (2017).

   Article 
   PubMed 

   Google Scholar 

5. Neumann, G. & Kawaoka, Y. Transmission of influenza A viruses. Virology 479–480, 234–246 (2015).

   Article 
   PubMed 

   Google Scholar 

6. Koutsakos, M., Nguyen, T. H., Barclay, W. S. & Kedzierska, K. Knowns and unknowns of influenza B viruses. Future Microbiol. 11, 119–135 (2015).

   Article 
   PubMed 

   Google Scholar 

7. van de Sandt, C. E., Bodewes, R., Rimmelzwaan, G. F. & de Vries, R. D. Influenza B viruses: not to be discounted. Future Microbiol. 10, 1447–1465 (2015).

   Article 
   PubMed 

   Google Scholar 

8. Francis, T. A new type of virus from epidemic influenza. Science 92, 405–408 (1940).

   Article 
   PubMed 

   Google Scholar 

9. Rota, P. A. et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175, 59–68 (1990).

   Article 
   CAS 
   PubMed 

   Google Scholar 

10. Zamarin, D., García-Sastre, A., Xiao, X., Wang, R. & Palese, P. Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog. 1, e4 (2005).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

11. Jagger, B. W. et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 337, 199–204 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

12. Fernandez-Sesma, A. et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J. Virol. 80, 6295–6304 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

13. Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383–397 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

14. Nelson, M. I. & Holmes, E. C. The evolution of epidemic influenza. Nat. Rev. Genet. 8, 196–205 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

15. Garten, R. J. et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325, 197–201 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

16. Koel, B. F. et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342, 976–979 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

17. Doud, M. B. & Bloom, J. D. Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses 8, 155 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

18. Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371–376 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

19. Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl Acad. Sci. USA 108, 20748–20753 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

20. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Epidemiol. Infect. 70, 767–777 (1972).

    Article 
    CAS 

    Google Scholar 

21. Bedford, T. et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature 523, 217–220 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

22. Vijaykrishna, D. et al. The contrasting phylodynamics of human influenza B viruses. eLife 4, e05055 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

23. Virk, R. K. et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc. Natl Acad. Sci. USA 117, 619–628 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

24. Langat, P. et al. Genome-wide evolutionary dynamics of influenza B viruses on a global scale. PLoS Pathog. 13, e1006749 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

25. Minter, A. et al. Estimation of seasonal influenza attack rates and antibody dynamics in children using cross-sectional serological data. J. Infect. Dis. 225, 1750–1754 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

26. Victora, G. D. & Wilson, P. C. Germinal center selection and the antibody response to influenza. Cell 163, 545–548 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

27. Guthmiller, J. J. et al. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 602, 314–320 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

28. Tsang, T. K. et al. Reconstructing antibody dynamics to estimate the risk of influenza virus infection. Nat. Commun. 13, 1557 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

29. Yang, B. et al. Life course exposures continually shape antibody profiles and risk of seroconversion to influenza. PLoS Pathog. 16, e1008635 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

30. Ranjeva, S. et al. Age-specific differences in the dynamics of protective immunity to influenza. Nat. Commun. 10, 1660 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

31. Ng, S. et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nat. Med. 25, 962–967 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

32. Hoa, L. N. M. et al. Influenza A(H1N1)pdm09 but not A(H3N2) virus infection induces durable seroprotection: results from the Ha Nam cohort. J. Infect. Dis. 226, 59–69 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

33. Wraith, S. et al. Homotypic protection against influenza in a pediatric cohort in Managua, Nicaragua. Nat. Commun. 13, 1190 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

34. Andrews, S. F. et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl Med. 7, 316ra192 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

35. Amitai, A. et al. Defining and manipulating B cell immunodominance hierarchies to elicit broadly neutralizing antibody responses against influenza virus. Cell Syst. 11, 573–588.e9 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

36. Labombarde, J. G. et al. Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. Cell Rep. 38, 110482 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

37. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181–193 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

38. Andrews, S. F. et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl Med. 7, 316ra192 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

39. Nachbagauer, R. et al. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. mBio 7, e01996-15 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

40. Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552–2558 (1993).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

41. Tan, G. S. et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86, 6179–6188 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

42. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

43. Meade, P. et al. Influenza virus infection induces a narrow antibody response in children but a broad recall response in adults. mBio 11, e03243-19 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

44. S, M. M. et al. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci. Transl Med. 5, 198ra107 (2013).

    Google Scholar 

45. Lessler, J. et al. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in Southern China. PLoS Pathog. 8, e1002802 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

46. Chen, Y.-Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429.e10 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

47. Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191–1199 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

48. Weiss, C. D. et al. Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A/H3N2 outbreak among unvaccinated military recruits. Clin. Infect. Dis. 71, 3096–3102 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

49. Maier, H. E. et al. Pre-existing antineuraminidase antibodies are associated with shortened duration of influenza A(H1N1)pdm virus shedding and illness in naturally infected adults. Clin. Infect. Dis. 70, 2290–2297 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

50. Dugan, H. L. et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. Sci. Transl Med. 12, eabd3601 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

51. Auladell, M. et al. Influenza virus infection history shapes antibody responses to influenza vaccination. Nat. Med. 28, 363–372 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

52. Lee, J. M. et al. Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. eLife 8, e49324 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

53. Doud, M. B., Lee, J. M. & Bloom, J. D. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat. Commun. 9, 1386 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

54. Medina, R. A. et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci. Transl Med. 5, 187ra70 (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

55. Altman, M. O. et al. Human influenza a virus hemagglutinin glycan evolution follows a temporal pattern to a glycan limit. mBio 10, e00204-19 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

56. Gerhard, W., Yewdell, J., Frankel, M. E. & Webster, R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290, 713–717 (1981).

    Article 
    CAS 
    PubMed 

    Google Scholar 

57. Webster, R. G. & Laver, W. G. Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. Virology 104, 139–148 (1980).

    Article 
    CAS 
    PubMed 

    Google Scholar 

58. Wiley, D. C., Wilson, I. A. & Skehel, J. J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373–378 (1981).

    Article 
    CAS 
    PubMed 

    Google Scholar 

59. Wang, Q., Cheng, F., Lu, M., Tian, X. & Ma, J. Crystal structure of unliganded influenza B virus hemagglutinin. J. Virol. 82, 3011–3020 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

60. Rosu, M. E. et al. Substitutions near the HA receptor binding site explain the origin and major antigenic change of the B/Victoria and B/Yamagata lineages. Proc. Natl Acad. Sci. USA 119, e2211616119 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

61. Barr, I. G. et al. WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 32, 4713–4725 (2014).

    Article 
    PubMed 

    Google Scholar 

62. Chai, N. et al. Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody. PLoS Pathog. 12, e1005702 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

63. Anderson, C. S. et al. Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain. Sci. Rep. 7, 4265 (2017).

    Article 

    Google Scholar 

64. Wang, W. et al. Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it. PLoS ONE 14, e0222436 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

65. Park, J. K. et al. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model. Nat. Med. 26, 1240–1246 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

66. Lee, C.-Y. et al. Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies. Proc. Natl Acad. Sci. USA 120, e2208718120 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

67. Wu, N. C. et al. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Science 368, 1335–1340 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

68. Colman, P. M., Varghese, J. N. & Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303, 41–44 (1983).

    Article 
    CAS 
    PubMed 

    Google Scholar 

69. Colman, P. M. et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 326, 358–363 (1987).

    Article 
    CAS 
    PubMed 

    Google Scholar 

70. Webster, R. G., Brown, L. E. & Laver, W. G. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 135, 30–42 (1984).

    Article 
    CAS 
    PubMed 

    Google Scholar 

71. Krammer, F. et al. NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, e02332-17 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

72. Air, G. M., Els, M. C., Brown, L. E., Laver, W. G. & Webster, R. G. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology 145, 237–248 (1985).

    Article 
    CAS 
    PubMed 

    Google Scholar 

73. Varghese, J. N., Webster, R. G., Laver, W. G. & Colman, P. M. Structure of an escape mutant of glycoprotein N2 neuraminidase of influenza virus A/Tokyo/3/67 at 3 Å. J. Mol. Biol. 200, 201–203 (1988).

    Article 
    CAS 
    PubMed 

    Google Scholar 

74. Gulati, U. et al. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J. Virol. 76, 12274–12280 (2002).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

75. Westgeest, K. B. et al. Genetic evolution of the neuraminidase of influenza a (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J. Gen. Virol. 93, 1996–2007 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

76. Wan, H. et al. The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain. Nat. Microbiol. 4, 2216–2225 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

77. Powell, H. & Pekosz, A. Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding. PLoS Pathog. 16, e1008411 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

78. Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996–1000 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

79. Li, Z.-N. et al. Antibody landscape analysis following influenza vaccination and natural infection in humans with a high-throughput multiplex influenza antibody detection assay. mBio 12, e02808–e02820 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

80. Kucharski, A. J., Lessler, J., Cummings, D. A. T. & Riley, S. Timescales of influenza A/H3N2 antibody dynamics. PLoS Biol. 16, e2004974 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

81. Linderman, S. L. & Hensley, S. E. Antibodies with ‘original antigenic sin’ properties are valuable components of secondary immune responses to influenza viruses. PLoS Pathog. 12, e1005806 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

82. Arevalo, C. P. et al. Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies. Proc. Natl Acad. Sci. USA 117, 17221–17227 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

83. Dugan, H. L. & Wilson, P. C. Teach ’em young: influenza vaccines induce broadly neutralizing antibodies in children. Cell Rep. Med. 3, 100531 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

84. Gostic, K. M. et al. Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics. PLoS Pathog. 15, e1008109 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

85. Brouwer, A. F. et al. Birth cohort relative to an influenza A virus’s antigenic cluster introduction drives patterns of children’s antibody titers. PLoS Pathog. 18, e1010317 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

86. Arevalo, P., McLean, H. Q., Belongia, E. A. & Cobey, S. Earliest infections predict the age distribution of seasonal influenza A cases. eLife 9, e50060 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

87. Vieira, M. C. et al. Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases. Nat. Commun. 12, 4313 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

88. Gagnon, A., Acosta, E. & Miller, M. S. Age-specific incidence of influenza A responds to change in virus subtype dominance. Clin. Infect. Dis. 71, e195–e198 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

89. Gouma, S. et al. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat. Commun. 11, 4566 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

90. Linderman, S. L. et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc. Natl Acad. Sci. USA 111, 15798–15803 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

91. Li, Y. et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210, 1493–1500 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

92. Xu, R. et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357–360 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

93. Gostic, K. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354, 722–726 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

94. Horns, F., Vollmers, C., Dekker, C. L. & Quake, S. R. Signatures of selection in the human antibody repertoire: selective sweeps, competing subclones, and neutral drift. Proc. Natl Acad. Sci. USA 116, 1261–1266 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

95. Vollmers, C., Sit, R. V., Weinstein, J. A., Dekker, C. L. & Quake, S. R. Genetic measurement of memory B-cell recall using antibody repertoire sequencing. Proc. Natl Acad. Sci. USA 110, 13463–13468 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

96. Jiang, N. et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci. Transl Med. 5, 171ra19 (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

97. Horns, F., Dekker, C. L. & Quake, S. R. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep. 30, 905–913.e6 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

98. Lee, J. et al. Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations. Cell Host Microbe 25, 367–376.e5 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

99. Lee, J. et al. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat. Med. 22, 1456–1464 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

100. Hoehn, K. B. et al. Human B cell lineages associated with germinal centers following influenza vaccination are measurably evolving. eLife 10, e70873 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

101. Hoehn, K. B. et al. Repertoire-wide phylogenetic models of B cell molecular evolution reveal evolutionary signatures of aging and vaccination. Proc. Natl Acad. Sci. USA 116, 22664–22672 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

102. Schmidt, A. G. et al. Immunogenic stimulus for germline precursors of antibodies that engage the influenza hemagglutinin receptor-binding site. Cell Rep. 13, 2842–2850 (2015).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

103. Tesini, B. L. et al. Broad hemagglutinin-specific memory B cell expansion by seasonal influenza virus infection reflects early-life imprinting and adaptation to the infecting virus. J. Virol. 93, e00169-19 (2019).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

104. de Bourcy, C. F. A. et al. Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging. Proc. Natl Acad. Sci. USA 114, 1105–1110 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

105. Ju, C.-H. et al. Plasmablast antibody repertoires in elderly influenza vaccine responders exhibit restricted diversity but increased breadth of binding across influenza strains. Clin. Immunol. 193, 70–79 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

106. Henry, C. et al. Influenza virus vaccination elicits poorly adapted B cell responses in elderly individuals. Cell Host Microbe 25, 357–366.e6 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

107. Lee, J. M. et al. Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants. Proc. Natl Acad. Sci. USA 115, E8276–E8285 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

108. Skehel, J. J. et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl Acad. Sci. USA 81, 1779–1783 (1984).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

109. Das, S. R. et al. Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc. Natl Acad. Sci. USA 108, E1417-22 (2011).

     Article 
     PubMed 

     Google Scholar 

110. Hensley, S. E. et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326, 734–736 (2009).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

111. Broecker, F. et al. Immunodominance of antigenic site B in the hemagglutinin of the current H3N2 influenza virus in humans and mice. J. Virol. 92, e01100-18 (2018).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

112. Wu, N. C. & Wilson, I. A. A perspective on the structural and functional constraints for immune evasion: insights from influenza virus. J. Mol. Biol. 429, 2694–2709 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

113. Wu, N. C. et al. Major antigenic site B of human influenza H3N2 viruses has an evolving local fitness landscape. Nat. Commun. 11, 1233 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

114. Wu, N. C. et al. A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site. Nat. Commun. 9, 1264 (2018).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

115. Wu, N. C. et al. Diversity of functionally permissive sequences in the receptor-binding site of influenza hemagglutinin. Cell Host Microbe 21, 742–753.e8 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

116. Bloom, J. D., Gong, L. I. & Baltimore, D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328, 1272–1275 (2010).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

117. Duan, S. et al. Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat. Commun. 5, 5029 (2014).

     Article 
     CAS 
     PubMed 

     Google Scholar 

118. Wang, Y., Lei, R., Nourmohammad, A. & Wu, N. C. Antigenic evolution of human influenza H3N2 neuraminidase is constrained by charge balancing. eLife 10, e72516 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

119. Lei, R. et al. Prevalence and mechanisms of evolutionary contingency in human influenza H3N2 neuraminidase. Nat. Commun. 13, 6443 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

120. Mitnaul, L. J. et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J. Virol. 74, 6015–6020 (2000).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

121. Kosik, I. & Yewdell, J. W. Influenza hemagglutinin and neuraminidase: Yin–Yang proteins coevolving to thwart immunity. Viruses 11, 346 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

122. Lakdawala, S. S. et al. Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog. 7, e1002443 (2011).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

123. Xu, R. et al. Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. J. Virol. 86, 9221–9232 (2012).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

124. de Vries, E., Du, W., Guo, H. & de Haan, C. A. M. Influenza A virus hemagglutinin–neuraminidase–receptor balance: preserving virus motility. Trends Microbiol. 28, 57–67 (2020).

     Article 
     PubMed 

     Google Scholar 

125. Liu, T., Wang, Y., Tan, T. J. C., Wu, N. C. & Brooke, C. B. The evolutionary potential of influenza A virus hemagglutinin is highly constrained by epistatic interactions with neuraminidase. Cell Host Microbe 30, 1363–1369.e4 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

126. Westgeest, K. B. et al. Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011. J. Virol. 88, 2844–2857 (2014).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

127. Rambaut, A. et al. The genomic and epidemiological dynamics of human influenza A virus. Nature 453, 615–619 (2008).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

128. Müller, N. F., Stolz, U., Dudas, G., Stadler, T. & Vaughan, T. G. Bayesian inference of reassortment networks reveals fitness benefits of reassortment in human influenza viruses. Proc. Natl Acad. Sci. USA 117, 17104–17111 (2020).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

129. Potter, B. I. et al. Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017–2018 influenza season. Virus Evol. 5, vez046 (2019).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

130. Chen, R. & Holmes, E. C. The evolutionary dynamics of human influenza B virus. J. Mol. Evol. 66, 655–663 (2008).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

131. Dudas, G., Bedford, T., Lycett, S. & Rambaut, A. Reassortment between influenza B lineages and the emergence of a coadapted PB1-PB2-HA gene complex. Mol. Biol. Evol. 32, 162–172 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

132. Kim, Jil. et al. Reassortment compatibility between PB1, PB2, and HA genes of the two influenza B virus lineages in mammalian cells. Sci. Rep. 6, 27480 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

133. Lakdawala, S. S. et al. Influenza A virus assembly intermediates fuse in the cytoplasm. PLoS Pathog. 10, e1003971 (2014).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

134. Gog, J. R. et al. Codon conservation in the influenza A virus genome defines RNA packaging signals. Nucleic Acids Res. 35, 1897–1907 (2007).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

135. Dadonaite, B. et al. The structure of the influenza A virus genome. Nat. Microbiol. 4, 1781–1789 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

136. le Sage, V. et al. Mapping of influenza virus RNA-RNA interactions reveals a flexible network. Cell Rep. 31, 107823 (2020).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

137. Jones, J. E. et al. Parallel evolution between genomic segments of seasonal human influenza viruses reveals RNA-RNA relationships. eLife 10, e66525 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

138. McCrone, J. T. et al. Stochastic processes constrain the within and between host evolution of influenza virus. eLife 7, e35962 (2018).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

139. Debbink, K. et al. Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. PLoS Pathog. 13, e1006194 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

140. Sobel Leonard, A. et al. Deep sequencing of influenza A virus from a human challenge study reveals a selective bottleneck and only limited intrahost genetic diversification. J. Virol. 90, 11247–11258 (2016).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

141. Dinis, J. M. et al. Deep sequencing reveals potential antigenic variants at low frequencies in influenza A virus-infected humans. J. Virol. 90, 3355–3365 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

142. Valesano, A. L. et al. Influenza B viruses exhibit lower within-host diversity than influenza A viruses in human hosts. J. Virol. 94, e01710–e01719 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

143. Han, A. X., Maurer-Stroh, S. & Russell, C. A. Individual immune selection pressure has limited impact on seasonal influenza virus evolution. Nat. Ecol. Evol. 3, 302–311 (2019).

     Article 
     PubMed 

     Google Scholar 

144. Xue, K. S. & Bloom, J. D. Linking influenza virus evolution within and between human hosts. Virus Evol. 6, 812016 (2020).

     Article 

     Google Scholar 

145. Lumby, C. K., Zhao, L., Breuer, J. & Illingworth, C. J. R. A large effective population size for established within-host influenza virus infection. eLife 9, e56915 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

146. Xue, K. S. et al. Parallel evolution of influenza across multiple spatiotemporal scales. eLife 6, e26875 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

147. Xue, K. S. & Bloom, J. D. Reconciling disparate estimates of viral genetic diversity during human influenza infections. Nat. Genet. 51, 1298–1301 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

148. Ghafari, M., Lumby, C. K., Weissman, D. B. & Illingworth, C. J. R. Inferring transmission bottleneck size from viral sequence data using a novel haplotype reconstruction method. J. Virol. 94, e00014-20 (2020).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

149. Morris, D. H. et al. Asynchrony between virus diversity and antibody selection limits influenza virus evolution. eLife 9, e62105 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

150. Amato, K. A. et al. Influenza A virus undergoes compartmentalized replication in vivo dominated by stochastic bottlenecks. Nat. Commun. 13, 3416 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

151. Neuzil, K. M. et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J. Infect. Dis. 194, 1032–1039 (2006).

     Article 
     CAS 
     PubMed 

     Google Scholar 

152. Ng, S. et al. The timeline of influenza virus shedding in children and adults in a household transmission study of influenza in Managua, Nicaragua. Pediatr. Infect. Dis. J. 35, 583–586 (2016).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

153. Han, A. X. et al. Within-host evolutionary dynamics of seasonal and pandemic human influenza A viruses in young children. eLife 10, e68917 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

154. Hurt, A. C. Antiviral therapy for the next influenza pandemic. Trop. Med. Infect. Dis. 4, 67 (2019).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

155. Hayden, F. G. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus Infections. N. Engl. J. Med. 337, 874–880 (1997).

     Article 
     CAS 
     PubMed 

     Google Scholar 

156. Nicholson, K. G. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355, 1845–1850 (2000).

     Article 
     CAS 
     PubMed 

     Google Scholar 

157. Kohno, S., Kida, H., Mizuguchi, M. & Shimada, J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54, 4568–4574 (2010).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

158. Hayden, F. G. et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379, 913–923 (2018).

     Article 
     CAS 
     PubMed 

     Google Scholar 

159. Koel, B. F. et al. Longitudinal sampling is required to maximize detection of intrahost A/H3N2 virus variants. Virus Evol. 6, veaa088 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

160. Omoto, S. et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 8, 9633 (2018).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

161. Holmes, E. C. et al. Understanding the impact of resistance to influenza antivirals. Clin. Microbiol. Rev. 34, e00224-20 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

162. Du, Z., Nugent, C., Galvani, A. P., Krug, R. M. & Meyers, L. A. Modeling mitigation of influenza epidemics by baloxavir. Nat. Commun. 11, 2750 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

163. Han, A. X. et al. Estimating the potential need and impact of SARS-CoV-2 test-and-treat programs with oral antivirals in low-and-middle-income countries. Preprint at medRxiv, https://doi.org/10.1101/2022.10.05.22280727 (2022).

164. Clark, T. W. et al. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. Lancet Respir. Med. 9, 419–429 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

165. Gal, M. et al. Matching diagnostics development to clinical need: target product profile development for a point of care test for community-acquired lower respiratory tract infection. PLoS ONE 13, e0200531 (2018).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

166. Kotnik, J. H. et al. Flu@home: the comparative accuracy of an at-home influenza rapid diagnostic test using a prepositioned test kit, mobile app, mail-in reference sample, and symptom-based testing trigger. J. Clin. Microbiol. 60, e0207021 (2022).

     Article 
     PubMed 

     Google Scholar 

167. Yamayoshi, S. & Kawaoka, Y. Current and future influenza vaccines. Nat. Med. 25, 212–220 (2019).

     Article 
     CAS 
     PubMed 

     Google Scholar 

168. Gerdil, C. The annual production cycle for influenza vaccine. Vaccine 21, 1776–1779 (2003).

     Article 
     PubMed 

     Google Scholar 

169. Gouma, S., Weirick, M. & Hensley, S. E. Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine. Nat. Commun. 11, 2445 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

170. Flannery, B. et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018–2019 season. J. Infect. Dis. 221, 8–15 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

171. Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA 114, 12578–12583 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

172. Wu, N. C. et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 13, e1006682 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

173. Wu, N. C. et al. Preventing an antigenically disruptive mutation in egg-based H3N2 seasonal influenza vaccines by mutational incompatibility. Cell Host Microbe 25, 836–844.e5 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

174. Wei, C. J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239–252 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

175. Dunkle, L. M. et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N. Engl. J. Med. 376, 2427–2436 (2017).

     Article 
     CAS 
     PubMed 

     Google Scholar 

176. Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

177. Moderna. Moderna announces positive interim phase 1 data for mRNA flu vaccine and provides program update. Moderna https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Positive-Interim-Phase-1-Data-for-mRNA-Flu-Vaccine-and-Provides-Program-Update/default.aspx (2021).

178. Nachbagauer, R. & Krammer, F. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect. 23, 222–228 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

179. Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

180. Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065–1070 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

181. Bernstein, D. I. et al. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect. Dis. 20, 80–91 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

182. Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623–628 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

183. Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569–1584 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

184. McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl Acad. Sci. USA 119, e2206333119 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

185. Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

186. Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

187. Turner, J. S. et al. Human germinal centres engage memory and naive B cells after influenza vaccination. Nature 586, 127–132 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

188. Zarnitsyna, V. I. et al. Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza. Philos. Trans. R. Soc. B Biol. Sci. 370, 20140248 (2015).

     Article 

     Google Scholar 

189. Kim, J. H., Skountzou, I., Compans, R. & Jacob, J. Original antigenic sin responses to influenza viruses. J. Immunol. 183, 3294–3301 (2009).

     Article 
     CAS 
     PubMed 

     Google Scholar 

190. Mesin, L. et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation boosting. Cell 180, 92–106.e11 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

191. Paules, C. I., Sullivan, S. G., Subbarao, K. & Fauci, A. S. Chasing seasonal influenza — the need for a universal influenza vaccine. N. Engl. J. Med. 378, 7–9 (2018).

     Article 
     PubMed 

     Google Scholar 

192. Olson, S. M. et al. Vaccine effectiveness against life-threatening influenza illness in US children. Clin. Infect. Dis. 75, 230–238 (2022).

     Article 
     PubMed 

     Google Scholar 

193. Tenforde, M. W. et al. Influenza vaccine effectiveness against hospitalization in the United States, 2019–2020. J. Infect. Dis. 224, 813–820 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

194. Ortiz, J. R. & Neuzil, K. M. Influenza immunization in low- and middle-income countries: preparing for next-generation influenza vaccines. J. Infect. Dis. 219, S97–S106 (2019).

     Article 
     PubMed 

     Google Scholar 

195. Yang, H. et al. Structure and receptor binding preferences of recombinant human A(H3N2) virus hemagglutinins. Virology 477, 18–31 (2015).

     Article 
     CAS 
     PubMed 

     Google Scholar 

196. Feng, L. et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat. Commun. 12, 3249 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

197. Qi, Y., Shaman, J. & Pei, S. Quantifying the impact of COVID-19 nonpharmaceutical interventions on influenza transmission in the United States. J. Infect. Dis. 224, 1500–1508 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

198. Huang, Q. S. et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat. Commun. 12, 1001 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

199. Dhanasekaran, V. et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat. Commun. 13, 1721 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

200. Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 19, 741–742 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

201. Baker, R. E. et al. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc. Natl Acad. Sci. USA 117, 30547–30553 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

202. Ali, S. T. et al. Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: a modelling study. Lancet Glob. Health 10, e1612–e1622 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

203. Nielsen, J. et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clin. Microbiol. Infect. 25, 1266–1276 (2019).

     Article 
     CAS 
     PubMed 

     Google Scholar 

204. Borchering, R. K. et al. Anomalous influenza seasonality in the United States and the emergence of novel influenza B viruses. Proc. Natl Acad. Sci. USA 118, e2012327118 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

205. Tan, J., Asthagiri Arunkumar, G. & Krammer, F. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? Curr. Opin. Immunol. 53, 45–50 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

Download references